Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: Changes in Use of Neoadjuvant Chemotherapy Over Time—Highest Rates of Use Now in Triple-Negative and HER2+ Disease

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Haddad TC, Goetz MP. Landscape of neoadjuvant therapy for breast cancer. Ann Surg Oncol. 2015;22(5):1408–15.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Untch M, Konecny GE, Paepke S, von Minckwitz G. Current and future role of neoadjuvant therapy for breast cancer. Breast 2014;23(5):526–37.

    Article  PubMed  Google Scholar 

  3. Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg. 2014;260(4):608-14; discussion 614–6.

    Article  Google Scholar 

  4. Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC. Neoadjuvant chemotherapy use in breast cancer is greatest in excellent responders: triple-negative and HER2+ subtypes. Ann Surg Oncol. 2018;25(8):2241–8.

    Article  PubMed  Google Scholar 

  5. Nandy A, Gangopadhyay S, Mukhopadhyay A. Individualizing breast cancer treatment: the dawn of personalized medicine. Exp Cell Res. 2014;320(1):1–11.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Mayo Clinic, Rochester, MN, USA

    Brittany L. Murphy MD MS & Judy C. Boughey MD

  2. The Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA

    Brittany L. Murphy MD MS

Authors
  1. Brittany L. Murphy MD MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Judy C. Boughey MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Judy C. Boughey MD.

Ethics declarations

Disclosures

The authors have no conflicts of interest to disclose.

Additional information

ASO Author Reflections is a brief invited commentary on the article, “Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes.” Ann Surg Oncol. 2018;25:2241–2248.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Murphy, B.L., Boughey, J.C. ASO Author Reflections: Changes in Use of Neoadjuvant Chemotherapy Over Time—Highest Rates of Use Now in Triple-Negative and HER2+ Disease. Ann Surg Oncol 25 (Suppl 3), 695–696 (2018). https://doi.org/10.1245/s10434-018-7046-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-018-7046-9

Keywords

Search

Navigation